Get the Stockscreener App
4.12
3.78%
0.15
After Hours:
4.14
0.02
+0.49%
Chimerix Inc stock is traded at $4.12, with a volume of 1.96M.
It is up +3.78% in the last 24 hours and up +16.38% over the past month.
Chimerix Inc. is a biopharmaceutical company based in the United States that engages in the research, development, and commercialization of medicines. Its portfolio includes treatment for acute myeloid leukemia (or AML) and antiviral treatment for smallpox. The company generates revenue through revenue related to non-refundable upfront fees, royalties and milestone payments earned under license agreements, also by royalty revenue related to sales of TEMBEXA made by Emergent after the Asset Sale. The company operates only in one business segment namely pharmaceuticals.
See More
Previous Close:
$3.97
Open:
$4.07
24h Volume:
1.96M
Relative Volume:
0.47
Market Cap:
$370.69M
Revenue:
$324.00K
Net Income/Loss:
$-82.10M
P/E Ratio:
-4.4301
EPS:
-0.93
Net Cash Flow:
$-69.18M
1W Performance:
+0.24%
1M Performance:
+16.38%
6M Performance:
+388.21%
1Y Performance:
+343.49%
1-Day Range:
$3.98
$4.17
1-Week Range:
$3.78
$4.20
52-Week Range:
$0.75
$4.22
Chimerix Inc Stock (CMRX) Company Profile
Name
Chimerix Inc
Sector
Industry
Phone
919.806.1074
Address
2505 MERIDIAN PARKWAY, SUITE 100, DURHAM, NC
Compare CMRX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CMRX
Chimerix Inc
|
4.12 | 370.69M | 324.00K | -82.10M | -69.18M | -0.93 |
|
VRTX
Vertex Pharmaceuticals Inc
|
481.16 | 123.91B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
722.07 | 78.94B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
657.97 | 39.98B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
278.25 | 35.89B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
119.94 | 28.75B | 3.30B | -501.07M | 1.03B | -2.1146 |
Chimerix Inc Stock (CMRX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-23-23 | Initiated | Robert W. Baird | Outperform |
| Sep-07-22 | Initiated | CapitalOne | Overweight |
| Apr-29-21 | Initiated | Maxim Group | Buy |
| Apr-23-21 | Resumed | Cowen | Outperform |
| Mar-31-21 | Initiated | Jefferies | Buy |
| Mar-31-21 | Initiated | Wedbush | Outperform |
| Feb-14-18 | Downgrade | JP Morgan | Neutral → Underweight |
| Feb-02-18 | Initiated | H.C. Wainwright | Buy |
| Aug-09-16 | Reiterated | FBR Capital | Mkt Perform |
| Feb-23-16 | Downgrade | Barclays | Overweight → Equal Weight |
| Feb-23-16 | Reiterated | FBR Capital | Mkt Perform |
| Feb-23-16 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| Feb-22-16 | Downgrade | Citigroup | Buy → Neutral |
| Dec-29-15 | Downgrade | JP Morgan | Overweight → Neutral |
| Dec-28-15 | Downgrade | FBR Capital | Outperform → Mkt Perform |
| Dec-28-15 | Reiterated | Piper Jaffray | Overweight |
| Dec-17-15 | Initiated | UBS | Buy |
| Oct-05-15 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Sep-03-15 | Initiated | Citigroup | Buy |
| Aug-18-15 | Initiated | FBR Capital | Outperform |
| Aug-06-15 | Reiterated | Brean Capital | Buy |
| May-11-15 | Reiterated | Brean Capital | Buy |
| Mar-04-15 | Initiated | Barclays | Overweight |
| Feb-12-15 | Reiterated | Stifel | Buy |
| Dec-31-14 | Reiterated | Brean Capital | Buy |
| Jul-08-14 | Resumed | Brean Capital | Buy |
View All
Chimerix Inc Stock (CMRX) Latest News
Its Stock Has Paid Off Big Time For Chimerix Inc - SETE News
CMRX stock rated an Outperform by Robert W. Baird - Knox Daily
Market Highlights: Chimerix Inc (CMRX) Ends on a Low Note at 3.80 - The Dwinnex
Chimerix (NASDAQ:CMRX) Shares Cross Above 200-Day Moving AverageHere's What Happened - MarketBeat
Chimerix, Inc. (NASDAQ:CMRX) VP Sells $11,480.00 in Stock - MarketBeat
Chimerix stock soars to 52-week high, hits $4.22 - MSN
CMRX Stock Skyrockets in 3 Months: Here's What You Should Know - Yahoo Finance
Chimerix stock soars to 52-week high, hits $4.22 By Investing.com - Investing.com UK
Chimerix (NASDAQ:CMRX) Share Price Passes Above Two Hundred Day Moving Average – Here’s Why - Defense World
Chimerix Leadership Reveals Future Growth Strategy at Elite Healthcare Conference - StockTitan
Chimerix Grants Stock Options to New Employees, Advances Drug Development - StockTitan
Chimerix stock soars to 52-week high, hits $3.8 - MSN
Chimerix stock soars to 52-week high, hits $3.8 By Investing.com - Investing.com Australia
Assenagon Asset Management S.A. Purchases 496,823 Shares of Chimerix, Inc. (NASDAQ:CMRX) - MarketBeat
Assenagon Asset Management S.A. Has $2.85 Million Holdings in Chimerix, Inc. (NASDAQ:CMRX) - Defense World
Here’s Why Chimerix, Inc. (CMRX) Is Skyrocketing - MSN
Chimerix, Inc. (NASDAQ:CMRX) Sees Large Decline in Short Interest - MarketBeat
Why These 24 Stocks Are Skyrocketing - Insider Monkey
Chimerix to Speak Today at The White House Cancer Moonshot Forum - The Manila Times
Chimerix CSO to Present at Biden Cancer Moonshot Forum on Breakthrough Brain Cancer Treatment - StockTitan
Geode Capital Management LLC Trims Holdings in Chimerix, Inc. (NASDAQ:CMRX) - Defense World
Chimerix stock soars to 52-week high, hits $3.73 By Investing.com - Investing.com South Africa
Chimerix (NASDAQ:CMRX) Shares Pass Above 50-Day Moving AverageHere's What Happened - MarketBeat
Chimerix stock soars to 52-week high, hits $3.73 - Investing.com
Chimerix asks FDA to approve oral dordaviprone as glioma treatment - Myeloma Research News
H.C. Wainwright reiterates Buy rating on Chimerix stock amid NDA submission for ONC201 - Investing.com Canada
Buy rating reaffirmed on Chimerix stock with potential 3Q25 launch for ONC201 - Investing.com Australia
Buy rating reaffirmed on Chimerix stock with potential 3Q25 launch for ONC201 By Investing.com - Investing.com South Africa
Chimerix (NASDAQ:CMRX) Given Buy Rating at HC Wainwright - Defense World
Chimerix (NASDAQ: CMRX) Enters Amended Loan Agreement with Silicon Valley Bank - Defense World
Chimerix takes pivotal step for novel brain cancer drug - The Business Journals
A Glimpse Into The Expert Outlook On Chimerix Through 4 Analysts - Benzinga
Chimerix's (CMRX) "Buy" Rating Reaffirmed at HC Wainwright - MarketBeat
Chimerix, Inc. Submits Dordaviprone New Drug Application for Accelerated Approval to U.S. FDA for Patients with Recurrent H3 K27M-Mutant Diffuse Glioma - Marketscreener.com
Chimerix (CMRX) Submits Dordaviprone New Drug Application for Accelerated Approval to U.S. FDA for Patients with Recurrent H3 K27M-Mutant Diffuse Glioma - StreetInsider.com
Chimerix Files FDA Application for Novel Brain Cancer Drug Dordaviprone, Secures $30M Launch Funding - StockTitan
Chimerix stock soars to 52-week high, hits $3.44 By Investing.com - Investing.com Nigeria
Chimerix stock soars to 52-week high, hits $3.44 - Investing.com India
Chimerix, Inc. (NASDAQ:CMRX) Short Interest Update - MarketBeat
Chimerix, Inc. (NASDAQ:CMRX) Sees Significant Drop in Short Interest - MarketBeat
Biodefense Market CAGR of 7.3% Size, Growth Drivers and Forecast 2024-2031 | XOMA corporation, Altimmune Inc., - EIN News
Wedbush Weighs in on Chimerix’s Q4 Earnings (NASDAQ:CMRX) - Defense World
Chimerix Inc Stock (CMRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.82%
0.53%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):